ERLEADA® (apalutamide)

As soon as you diagnose mCSPC or nmCRPC…



The articles above may only be available to subscribers of the respective journals. To access this content, you may have to sign in using your personal or institutional credentials. If you are not registered or a member of these journals, then you may need to purchase the articles through their sites.

Your One Source for Access, Affordability, and Treatment Support for Your Patients

Call a Janssen CarePath Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 AM to 8:00 PM ET.

Sign Up or Log In to the Provider Portal at


Download a list of specialty pharmacies that distribute ERLEADA®.

Secondary endpoint.

‡All patients who enrolled in the TITAN study started ADT for mCSPC ≤6 months prior to randomization.3

§In the SPARTAN study, conventional imaging (technetium-99m bone scans and CT scans) was used to confirm that patients were non-metastatic at screening for inclusion. Patients with pelvic lymph nodes <2 cm in short axis (N1) located below the iliac bifurcation at screening were allowed in the study. All patients in SPARTAN had a PSA doubling time ≤10 months at study entry.2,4

ADT = androgen deprivation therapy; AR = androgen receptor; CI = confidence interval; CT = computed tomography; HR = hazard ratio; mCSPC = metastatic castration-sensitive prostate cancer; MFS = metastasis-free survival; nmCRPC = non-metastatic castration-resistant prostate cancer; NR = not reached; OS = overall survival; PSA = prostate-specific antigen; SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509; TITAN = Targeted Investigational Treatment Analysis of Novel Antiandrogen.


1. Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study [published online April 29, 2021]. J Clin Oncol.

2. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

3. Chi KN, Agarwal N, Bjartell A, et al; for the TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13-24.

4. Smith MR, Saad F, Chowdhury S, et al; for the SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408-1418.